The US-based drug regulator, United States Food & Drug Administration (USFDA) concluded a remote record review of Shilpa Medicare's Unit III, R&D facility situated at Dabaspet, Bengaluru without any objectionable conditions or observations.
The review was conducted during Monday, 15 November 2021 to Thursday, 18 November 2021. Shilpa Medicare's Unit III Research & Development (R&D) facility in Dabaspet, Bengaluru (Karnataka) is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.
On a consolidated basis, Shilpa Medicare's net profit slumped 56% to Rs 19.89 crore on 5.9% increase in net sales to Rs 295.27 crore in Q2 September 2021 over Q2 September 2020.
Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.
Shares of Shilpa Medicare fell 0.70% to close at Rs 560.75 on Thursday, 18 November 2021. The domestic stock market is shut today, 19 November 2021 on account of Guru Nanak Jayanti.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app